U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C18H26NO3.NO3
Molecular Weight 366.4088
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLATROPINE NITRATE

SMILES

[O-][N+]([O-])=O.C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3

InChI

InChIKey=NEDVJZNVOSNSHF-KUMOIWDRSA-N
InChI=1S/C18H26NO3.NO3/c1-19(2)14-8-9-15(19)11-16(10-14)22-18(21)17(12-20)13-6-4-3-5-7-13;2-1(3)4/h3-7,14-17,20H,8-12H2,1-2H3;/q+1;-1/t14-,15+,16+,17?;

HIDE SMILES / InChI

Molecular Formula NO3
Molecular Weight 62.0049
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H26NO3
Molecular Weight 304.4039
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 3 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Methylatropine (methylatroponium) is a belladonna derivative. In 1902 the Bayer Company introduced atropine methonitrate, a quaternary ammonium salt of atropine (Eumydrin), as a mydriatic for dilation of the pupil during ophthalmic examination. Due to its highly polar nature it penetrates less readily into the central nervous system than atropine and was therefore introduced for relieving pyloric spasms in infants. Atropine methyl nitrate is a muscarinic acetylcholine receptor antagonist that does not cross the blood-brain barrier. Atropine methyl nitrate has been used for its peripheral muscarinic effects (targeting the bladder, respiratory tract, and to block parasympathetic signaling to the heart, among others) and to separate central from peripheral nervous system effects, or to protect against peripheral side effects when using muscarinics that do cross the blood brain barrier.

CNS Activity

Curator's Comment: Atropine methyl nitrate is a muscarinic acetylcholine receptor antagonist that does not cross the blood brain barrier.

Originator

Sources: https://www.ncbi.nlm.nih.gov/pubmed/18799813Helgolaender Wissenschaftliche Meeresuntersuchungen (1966), 14, (1-2), 583-90.
Curator's Comment: # Bayer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown

Approved Use

Unknown
Diagnostic
Eumydrin

Approved Use

Unknown

Launch Date

1901
Palliative
Eumydrin

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
0.8 mg multiple, oral (total)
Dose: 0.8 mg
Route: oral
Route: multiple
Dose: 0.8 mg
Sources:
unhealthy, 1 week
n = 1
Health Status: unhealthy
Age Group: 1 week
Population Size: 1
Sources:
Other AEs: Paralytic ileus, Hypotonic urinary bladder...
Other AEs:
Paralytic ileus (1 patient)
Hypotonic urinary bladder (1 patient)
Sources:
0.4 mg 6 times / day multiple, oral
Dose: 0.4 mg, 6 times / day
Route: oral
Route: multiple
Dose: 0.4 mg, 6 times / day
Sources:
unhealthy, 2 month
n = 1
Health Status: unhealthy
Age Group: 2 month
Sex: M
Population Size: 1
Sources:
Other AEs: Dilated pupils, Fever...
Other AEs:
Dilated pupils
Fever
Sources:
2.5 mL 1 times / day multiple, oral
Dose: 2.5 mL, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mL, 1 times / day
Sources:
unhealthy, 37 days
n = 1
Health Status: unhealthy
Age Group: 37 days
Sex: M
Population Size: 1
Sources:
Other AEs: Paralytic ileus...
Other AEs:
Paralytic ileus (grade 5)
Sources:
16 mg multiple, oral (total)
Highest studied dose
Dose: 16 mg
Route: oral
Route: multiple
Dose: 16 mg
Sources:
unhealthy, 7 weeks
n = 1
Health Status: unhealthy
Age Group: 7 weeks
Population Size: 1
Sources:
Other AEs: Irritable, Hypertonia...
Other AEs:
Irritable (1 patient)
Hypertonia (1 patient)
Dilated pupils (1 patient)
Sources:
0.1 mg 1 times / day multiple, oral (starting)
Dose: 0.1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 1 times / day
Sources:
unhealthy, babies
n = 15
Health Status: unhealthy
Age Group: babies
Population Size: 15
Sources:
Disc. AE: Abdominal distension...
AEs leading to
discontinuation/dose reduction:
Abdominal distension
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotonic urinary bladder 1 patient
0.8 mg multiple, oral (total)
Dose: 0.8 mg
Route: oral
Route: multiple
Dose: 0.8 mg
Sources:
unhealthy, 1 week
n = 1
Health Status: unhealthy
Age Group: 1 week
Population Size: 1
Sources:
Paralytic ileus 1 patient
0.8 mg multiple, oral (total)
Dose: 0.8 mg
Route: oral
Route: multiple
Dose: 0.8 mg
Sources:
unhealthy, 1 week
n = 1
Health Status: unhealthy
Age Group: 1 week
Population Size: 1
Sources:
Dilated pupils
0.4 mg 6 times / day multiple, oral
Dose: 0.4 mg, 6 times / day
Route: oral
Route: multiple
Dose: 0.4 mg, 6 times / day
Sources:
unhealthy, 2 month
n = 1
Health Status: unhealthy
Age Group: 2 month
Sex: M
Population Size: 1
Sources:
Fever
0.4 mg 6 times / day multiple, oral
Dose: 0.4 mg, 6 times / day
Route: oral
Route: multiple
Dose: 0.4 mg, 6 times / day
Sources:
unhealthy, 2 month
n = 1
Health Status: unhealthy
Age Group: 2 month
Sex: M
Population Size: 1
Sources:
Paralytic ileus grade 5
2.5 mL 1 times / day multiple, oral
Dose: 2.5 mL, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mL, 1 times / day
Sources:
unhealthy, 37 days
n = 1
Health Status: unhealthy
Age Group: 37 days
Sex: M
Population Size: 1
Sources:
Dilated pupils 1 patient
16 mg multiple, oral (total)
Highest studied dose
Dose: 16 mg
Route: oral
Route: multiple
Dose: 16 mg
Sources:
unhealthy, 7 weeks
n = 1
Health Status: unhealthy
Age Group: 7 weeks
Population Size: 1
Sources:
Hypertonia 1 patient
16 mg multiple, oral (total)
Highest studied dose
Dose: 16 mg
Route: oral
Route: multiple
Dose: 16 mg
Sources:
unhealthy, 7 weeks
n = 1
Health Status: unhealthy
Age Group: 7 weeks
Population Size: 1
Sources:
Irritable 1 patient
16 mg multiple, oral (total)
Highest studied dose
Dose: 16 mg
Route: oral
Route: multiple
Dose: 16 mg
Sources:
unhealthy, 7 weeks
n = 1
Health Status: unhealthy
Age Group: 7 weeks
Population Size: 1
Sources:
Abdominal distension Disc. AE
0.1 mg 1 times / day multiple, oral (starting)
Dose: 0.1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 1 times / day
Sources:
unhealthy, babies
n = 15
Health Status: unhealthy
Age Group: babies
Population Size: 15
Sources:
PubMed

PubMed

TitleDatePubMed
Clinical pertussis treated with methyl atropine nitrate (eumydrin).
1950 Oct 7
Ganglionic blocking action of atropine and methylatropine.
1953 Dec
The difference in the effects of tertiary and quaternary ammonium bases (proserine, serine, methylatropine and atropine) depending on the method of administration.
1962 Mar
Analysis of cardiac chronotropic responses to diazepam and bromazepam in conscious trained dogs.
1976 Feb
Influence of several anesthetic agents on the effect of delta9-tetrahydrocannabinol on the heart rate and blood pressure of the mongrel dog.
1977 Jul 1
Participation of cholinergic pathways in sinoaortic denervated rats.
1985
Apparent reduction in baroreflex sensitivity to adenosine in conscious dogs.
1985 Sep
Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin.
1986 Feb
Central interactions between dihydropyridines and cholinergic systems in the control of blood pressure in rat.
1987 Dec 1
L-glutamate stimulation of the zona incerta in the rat decreases heart rate and blood pressure.
1988 Aug 16
Endogenous gamma-aminobutyric acid (GABA) mediates ethanol inhibition of vagally mediated reflex bradycardia elicited from aortic baroreceptors.
1994 Feb
The role of cholinergic systems in the expression of morphine withdrawal.
1996 Jun
Bupivacaine inhibits baroreflex control of heart rate in conscious rats.
2000 Jan
Central muscarinic receptors signal pilocarpine-induced salivation.
2003 Dec
Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate.
2003 Dec
Cardiac effects of hypocretin-1 in nucleus ambiguus.
2003 Jun
Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow.
2003 Nov
Dual effects of acupuncture on gastric motility in conscious rats.
2003 Oct
Pharmacologic evidence for a parasympathetic role in seizure-induced neurocardiac regulatory abnormalities.
2004 Feb
Effects of angiotensin II on autonomic components of nasopharyngeal stimulation in male conscious rabbits.
2005 May
Effects of AV3V lesion on pilocarpine-induced pressor response and salivary gland vasodilation.
2005 Sep 7
Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in rats.
2006 Dec
Cardiovascular responses produced by central injection of hydrogen peroxide in conscious rats.
2006 Dec 11
Sympathetic and parasympathetic component of bradycardia triggered by stimulation of NTS P2X receptors.
2006 Feb
Medical countermeasure against respiratory toxicity and acute lung injury following inhalation exposure to chemical warfare nerve agent VX.
2007 Mar
Medullary pathways mediating the parasubthalamic nucleus depressor response.
2008 Apr
Acute induction of epileptiform discharges by pilocarpine in the in vitro isolated guinea-pig brain requires enhancement of blood-brain barrier permeability.
2008 Jan 2
Ghrelin infused into the portal vein inhibits glucose-stimulated insulin secretion in Wistar rats.
2008 Jul
Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications.
2010
Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.
2010 Jun 25
Final answer: ghrelin can suppress insulin secretion in humans, but is it clinically relevant?
2010 Nov
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: A drop of this solution placed on the surface of the tongue is rapidly absorbed and the treatment and absorption are not interfered with by the vomiting.
Pyloric stenosis: The first dose was usually 0.5-1 ml (0.05-0.1 mgm. per dose), increasing by 0.5 ml at each feed till a dose of 2-3 ml, six times daily, was reached, i.e. 1.2-1.8 mgm. in twenty-four hours.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:10:35 GMT 2023
Edited
by admin
on Fri Dec 15 15:10:35 GMT 2023
Record UNII
Q48D9J47K2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLATROPINE NITRATE
EP   USAN  
USAN  
Official Name English
EKOMINE
Brand Name English
ATROPINE METHYLNITRATE [MI]
Common Name English
ATROPINE METHONITRATE [MART.]
Common Name English
ATROPINE METHYL NITRATE
Common Name English
atropine methonitrate [INN]
Common Name English
ATROPINE METHYLNITRATE
MI   VANDF  
Common Name English
ATROPINE METHONITRATE
INN   JAN   MART.   WHO-DD  
INN  
Official Name English
Atropine methonitrate [WHO-DD]
Common Name English
8-AZONIABICYCLO(3.2.1)OCTANE, 3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8,8-DIMETHYL-, ENDO-(±)-, NITRATE (SALT)
Common Name English
ATROPINE METHYLNITRATE [VANDF]
Common Name English
ATROPINE METHONITRATE [JAN]
Common Name English
NSC-759122
Code English
8-METHYLATROPINIUM NITRATE
Common Name English
METHYLATROPINE NITRATE [EP IMPURITY]
Common Name English
EUMYDRIN
Brand Name English
N-METHYLATROPINE NITRATE
Common Name English
METHYLATROPINE NITRATE [USAN]
Common Name English
Code System Code Type Description
EVMPD
SUB12156MIG
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
INN
436
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
MERCK INDEX
m2136
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C174866
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
NSC
759122
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
EPA CompTox
DTXSID0045543
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-156-1
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
SMS_ID
100000079567
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
MESH
C006649
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
CAS
52-88-0
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
FDA UNII
Q48D9J47K2
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
ChEMBL
CHEMBL1187724
Created by admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY